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Since 1995, South Africa (SA) has used the syndromic management 
approach to manage sexually transmitted infections (STIs).[1] This 
approach uses standardised flow charts and treatment algorithms 
to identify and treat individuals with similar symptoms and clinical 
signs that are associated with common aetiologies.[2,3] Syndromic 
management was implemented in SA, as in other resource-limited 
settings, to address the limited laboratory capacity to diagnose 
the different causes before initiating appropriate treatment.[3] The 
introduction of syndromic management allowed STI treatment to be 
provided in the same visit without the risk of loss to follow-up and 
ongoing transmission to partners, at a cost that was affordable to the 
country. However, syndromic management has its disadvantages, 
mainly suboptimal performance in predicting presence of STIs, 
particularly in women with vaginal discharge syndrome (VDS). 
This suboptimal performance has been documented in diverse 
populations of women, including women living with HIV, women at 
high risk of HIV acquisition, and women attending STI services who 
were either symptomatic or asymptomatic.[3-11] When compared with 
the gold standard of laboratory diagnosis, syndromic management 
was found to have sensitivities (defined as the proportion of 
women with STIs who are classified as having VDS and therefore 
correctly treated) ranging from 5% to 100%.[3,11] Sensitivities of VDS 
syndromic management algorithms were higher for vaginal STI 
infections (bacterial vaginosis (BV) or Trichomonas vaginalis) than 
for cervical infections (Neisseria gonorrhoeae, Chlamydia trachomatis 
or Mycoplasma genitalium). On the other hand, VDS algorithms 
also have poor positive predictive values – defined as the proportion 
of women with VDS who turn out to have an STI on laboratory 
diagnosis and giving a measure of the proportions who are over-
treated according to the algorithm – ranging from 9% to 47.5%. [3,11] 
This poor performance means that some women with STIs go 
untreated, as infections can be asymptomatic, while others are 
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Background. Current South African guidelines for the management of vaginal discharge syndrome (VDS) do not recommend treatment 
for sexually transmitted infection (STI) pathogens for women aged ≥35 years whose partners do not have male urethritis syndrome. The 
guideline assumes that older women are unlikely to have an STI and that their partners do not have asymptomatic infections.
Objectives. To describe the demographic, behavioural and clinical characteristics of women with VDS, comparing older women (≥35 years) 
with younger women, and to determine the performance of age alone as a criterion for predicting the presence of STI.
Methods. This was a cross-sectional study at seven primary healthcare centres taking part in the aetiological surveillance of STIs between 
January 2015 and December 2016. Eligible women presenting with VDS were enrolled and completed a nurse-administered questionnaire. 
Genital swabs and blood specimens were collected for laboratory testing. Data were entered into surveillance-specific databases and 
exported into Stata 14 for analysis. Descriptive statistics were used to compare demographic and clinical profiles of older with younger 
women. A receiver operator curve (ROC) was used to determine the age cut-off that would best differentiate between women who had 
infection with STI pathogens and those without.
Results. Of 757 women enrolled, 157 (20.7%) were aged ≥35 years. HIV positivity was 46.6%, and higher in older than younger women 
(54.9% v. 44.5%; p=0.02). Of those enrolled, 283 (37.4%) had bacterial vaginosis (BV) and/or Candida infection only, 232 (30.7%) had BV 
or Candida with STI pathogens detected, 98 (13%) were infected with STI pathogens only, and 144 (19.0%) did not have any detectable STI 
or non-STI causes. Although older women were less likely than younger women to have Neisseria gonorrhoeae, Chlamydia trachomatis or 
Mycoplasma genitalium infection (23.6% v. 38.2%; p<0.01), the burden in older women was not negligible. The area under the ROC for age 
was 57.5% (95% confidence interval 53.2 - 61.8%), which implies suboptimal performance.
Conclusions. Although older women with VDS were less likely than younger women to have STIs, a significant proportion of them did have 
an infection with STI pathogens. Age alone was not a good criterion for discriminating between women with and without infection with 
STI pathogens. Other ways of improving the VDS algorithm performance are needed, as is better integration of HIV and STI prevention 
and treatment.
S Afr Med J 2018;108(10):876-880. DOI:10.7196/SAMJ.2018.v108i10.13027
877       October 2018, Vol. 108, No. 10
RESEARCH
treated unnecessarily. Syndromic management algorithms are also 
not useful for STI infections at extragenital sites such as the pharynx 
or anus.[12]
In the 2014 - 2015 fiscal year, 1.1 million people were treated 
for at least one new STI syndrome in SA.[13] VDS was common 
among STI clinic attendees, and seen in 42% of patients presenting 
with STI syndromes (National Institute for Communicable 
Diseases (NICD) sentinel surveillance data, unpublished). Current 
syndromic management guidelines for VDS recommend treatment 
with ceftriaxone, azithromycin and metronidazole for women aged 
<35 years or those who are older but have partners with symptoms of 
male urethritis syndrome (MUS).[14] This treatment covers the most 
common treatable and sexually transmitted causes of vaginal discharge 
in women, namely N. gonorrhoeae, C. trachomatis, T.  vaginalis and 
M.  genitalium. For women aged ≥35 years whose partners have no 
MUS, only metronidazole and clotrimazole therapy are recommended. 
This guideline assumes that these older women have BV or Candida 
infection only – traditionally considered to be non-STI causes of 
vaginal discharge.[14] The guidelines also assume that these women’s 
partners are not asymptomatic, although a significant proportion of 
at-risk males may have asymptomatic urethral STIs.[15] In addition, 
the syndromic management guidelines recommend behavioural risk 
reduction counselling, HIV testing and linkage to care and treatment, 
condom promotion, demonstration and provision, conception and 
contraception counselling, and partner management.
Objectives
To describe the demographic, behavioural and clinical characteristics 
of women with VDS enrolled at primary healthcare centres (PHCs) 
in SA, comparing those aged ≥35 years with those who were 
younger. We also assessed the performance of age as a criterion for 
excluding STIs and discuss the implications of the findings in terms 
of management of VDS in in the country.
Methods
Study design
This was a cross-sectional study of women aged ≥18 years presenting 
with VDS to seven STI sentinel surveillance sites in five provinces.
Setting
The Centre for HIV and STIs at the NICD has conducted sentinel 
site-based aetiological surveillance of STIs since 2004. The objective 
of the surveillance is to monitor the aetiological causes of STI 
syndromes and gonococcal antimicrobial resistance in SA. This 
surveillance also validates the recommended treatment regimens 
and ensures that the treatments included cover the most common 
causative STI pathogens for each syndrome. During the period 
1 January 2015 - 31 December 2016, sentinel surveillance was con-
ducted at seven PHCs located in five provinces – Eastern Cape, 
Gauteng, KwaZulu-Natal, Mpumalanga and North West.
Data collection
Following completion of eligibility assessment and informed consent 
procedures, consecutive women aged ≥18 years presenting with 
VDS to seven PHCs between January 2015 and December 2016 
were enrolled. Demographic and clinical data were collected using a 
nurse-administered questionnaire. Demographic variables included 
in the questionnaire included age, gender and race, while behavioural 
variables included condom use at last sexual encounter and having 
sexual partners from outside the country or province. Clinical 
variables were syndrome(s) diagnosed on the day of enrolment, 
treatment of STI syndromes in the preceding 12 months, non-
resolution of STI symptoms in the preceding 3 months, and referral 
from another STI treatment provider. Participants were asked to 
provide vaginal and endocervical swabs as well as venous blood 
specimens for laboratory testing. Surveillance questionnaires were 
linked to laboratory specimens through a barcode with a unique 
identification number. No other identifying information was 
collected.
Laboratory procedures
Specimens were transported to the STI reference laboratory at the 
NICD in Johannesburg. DNA was extracted from endocervical swabs 
using two automated DNA extractors (X-tractor Gene and QIAxtractor 
platforms; Qiagen, Germany). Swab-extracted DNA was tested using 
a validated in-house real-time multiplex polymerase chain reaction 
assay on the RotorGene platform (Qiagen) to detect the presence of 
the STI pathogens  N. gonorrhoeae, C. trachomatis, T. vaginalis and 
M. genitalium. Gram-stained smears of vaginal swab specimens were 
assessed microscopically for presence of BV (Nugent scoring) and 
Candida species. HIV seropositivity was determined using two rapid 
immunochromatographic assays, Unigold (Trinity Biotech, Ireland) 
and Alere Determine (Alere Medical Co. Ltd, Japan).
Data management and analysis
Data were captured into a study-specific Microsoft Access 2010 
database (Microsoft, USA) and exported into Stata 14 (StataCorp, 
USA) for analysis. Descriptive statistics was used to describe the 
women enrolled, comparing women aged ≥35 years with those 
who were younger. The χ2 test and rank-sum tests were used to test 
for associations between age category and other categorical and 
numerical variables. A p-value <0.05 was considered statistically 
significant. Simple proportions were used to describe the prevalence 
of STI and non-STI pathogen groups: (i) BV or Candida only; 
(ii) BV or Candida with STI pathogens; (iii) STI pathogens only; and 
(iv) no pathogens detected. A receiver operator curve (ROC) of age 
as a diagnostic criterion (with threshold values at 18 - 19, 20 - 21, 
22 - 23, 24 - 25, 26 - 28, 29 - 31, 32 - 34, 35 - 37, 38 - 40, 41 - 43, 
44 - 46, 47 - 49 and ≥50 years) was used to determine an age that 
would best predict the presence of the N. gonorrhoeae, C. trachomatis 
or M. genitalium infections and the area under the curve (AUC) 
determined. This AUC represents the probability of any age category 
selected at random correctly discriminating between women with 
any one or more of the three STI pathogens and those without. These 
three infections were chosen for use in the ROC analysis because 
in accordance with the existing VDS algorithm, they would be 
treated with ceftriaxone and azithromycin. These drugs would not 
be given to older women whose partners did not have MUS. The 
study had a planned sample size of 700 based on expected enrolment 
of 100 women per sentinel site. The sample size of 100 per site was 
considered sufficient to determine N. gonorrhoeae prevalence rates of 
between 12% and 22% assuming an alpha level of 0.05, power of 80% 
and no clustering of N. gonorrhoeae prevalence rates by site.
Ethical considerations
The study was approved by the University of the Witwatersrand 
Human Research Ethics Committee (ref. no. M160667). Written 
informed consent was obtained from all eligible women prior to 
administration of the questionnaire and specimen collection. To 
protect the privacy of the participants, the study was anonymous 
and unlinked. This means that no identifying information or contact 
details were collected and all study materials (questionnaires and 
specimens) were identified and linked through a unique study 
number. As syndromic management of STIs is standard of care for 
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VDS in SA, the laboratory results were not used for management and 
were not returned to participating women.
Results
Description of the study population
A total of 757 women were enrolled during the study period. 
The median age was 27 years (interquartile range (IQR) 22 - 32), 
157 (20.7%) were aged ≥35 years, and 750 (99.1%) were black 
Africans. Table 1 describes the demographic, behavioural and clinical 
characteristics of women by age category. Compared with the 
younger women, older women were more likely to report condom 
use at their last sexual encounter, but they were not different to the 
younger ones in respect of other behavioural factors or previous 
history of VDS. The overall HIV positivity was 46.6%, with older 
women more likely than younger women to be HIV-seropositive 
(54.9% v. 44.5%; p=0.022).
Prevalence of non-STI and STI causes of VDS by age
On laboratory testing, 283 women (37.4%) had BV and/or Candida 
infection without an STI; 232 (30.7%) had BV or Candida with at 
least one STI pathogen detected; 98 (12.9%) had one or more STI 
pathogens detected but without BV or Candida; while 144 (19.0%) 
did not have any detectable STI or non-STI causes. Compared 
with younger women (<35 years), older women were less likely 
to have BV and/or Candida with a concomitant STI (23.6% v. 
32.5%; p=0.013) but more likely to have no identifiable VDS 
aetiology (27.4% v. 16.8%; p=0.013). Although older women were 
significantly less likely than younger women to have N. gonorrhoeae, 
C. trachomatis or M. genitalium infection (23.6% v. 38.2%; p<0.001), 
the proportions of older women with these STI pathogens detected 
on an endocervical swab were 12.1%, 10.2% and 3.8%, respectively. 
Older women were also less likely than younger women to have 
Candida infection (12.1% v. 24.8%; p<0.001), but just as likely to 
have BV (50.3% v. 58.0%; p=0.084) or T. vaginalis infection (19.1% 
v. 13.0; p=0.051).
Performance of age as a criterion for predicting 
presence of STI pathogens
As age ≥35 years was significantly associated with lower (but not 
negligible) rates of STI infections in women presenting with VDS, an 
ROC was plotted to determine the age that best differentiated women 
with STI pathogens (N. gonorrhoeae, C. trachomatis or M. genitalium) 
from those without (Fig. 1 and Table 2). The curve for age was close 
to the chance level with no clear-cut age threshold located in the ROC 
space. The AUC was 57.5% (95% confidence interval 53.2 - 61.8), 
which implied suboptimal performance.
Discussion
The objectives of this study were to compare demographic, 
behavioural and clinical characteristics of older women (≥35 years) 
with VDS with those of younger women (<35 years) and to determine 
an age threshold that best differentiated between women with 
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Fig. 1. ROC for performance of age in predicting presence of Neisseria 
gonorrhoeae, Chlamydia trachomatis or Mycoplasma genitalium. (ROC = 
receiver operator curve.)
Table 1. Demographic, behavioural and clinical profiles of women with VDS by age at enrolment
Characteristic All (N=757)
Age <35 years 
(N=600)
Age ≥35 years 
(N=157) p-value 
Enrolment at rural site, n (%) 77 (10.2) 55 (9.2) 22 (14.0) 0.074
Age at first sex (years), median (IQR) 18 (16 - 19) 18 (16 - 19) 18 (16 - 20) 0.927
Condom use at last sexual encounter, n (%) 156 (20.1) 114 (19.0) 42 (26.8) 0.033
Treated for an STI syndrome in the past 12 months, n (%) 243 (32.1) 186 (31.0) 57 (36.3) 0.205
Non-resolution of symptoms or referral from another provider in the 
preceding 3 months, n (%)
68 (9.0) 55 (9.2) 13 (8.3) 0.729
Concomitant genital ulcer disease at enrolment, n (%) 62 (8.1) 54 (9.0) 8 (5.1) 0.112
Pathogen group 0.013
BV or Candida only 283 (37.4) 227 (37.8) 56 (35.7)
BV or Candida with an STI 232 (30.6) 195 (32.5) 37 (23.6)
STI only 98 (13.0) 77 (12.8) 21 (13.4)
No pathogen 144 (19.0) 101 (16.8) 43 (27.4)
Neisseria gonorrhoeae, n (%) 140 (18.5) 121 (20.2) 19 (12.1) 0.02
Chlamydia trachomatis, n (%) 134 (17.7) 118 (19.7) 16 (10.2) 0.006
Mycoplasma genitalium, n (%) 65 (8.6) 59 (9.8) 6 (3.8) 0.017
N. gonorrhoeae OR C. trachomatis OR M. genitalium, n (%) 266 (35.1) 229 (38.2) 37 (23.6) <0.001
Trichomonas vaginalis, n (%) 108 (14.3) 78 (13.0) 30 (19.1) 0.051
BV, n (%) 427 (56.4) 348 (58.0) 79 (50.3) 0.084
Candida, n (%) 167 (22.1) 148 (24.8) 19 (12.1) <0.001
HIV-positive, n (%) 353 (46.6) 267 (44.5) 86 (54.9) 0.022
VDS = vaginal discharge syndrome; IQR = interquartile range; STI = sexually transmitted infection; BV = bacterial vaginosis.
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treatable STI pathogens and those without. We found that although 
older women were significantly less likely than younger women to be 
infected with STI pathogens, the proportions of older women with 
detectable STI pathogens were not negligible. Moreover, there was no 
optimal age threshold that accurately differentiated between women 
with infection by treatable STI pathogens and those without.
These findings highlight a challenge that STI programmes in 
resource-limited settings face in improving the performance of 
VDS algorithms. Efforts to improve algorithm performance have 
sought to include other factors that may better distinguish the subset 
of VDS-positive women who have STIs from those with no STIs. 
Factors that have been evaluated include risk assessments based on 
self-reported high-risk sexual behaviour or a sexual history such as 
having a new sexual partner, having more than one sexual partner 
or having a symptomatic partner.[6] Other criteria have included 
vaginal examination, vaginal microscopy or point-of-care (POC) 
testing.[3] POC tests for N. gonorrhoeae or C. trachomatis alone or 
in combination conducted on urine, vaginal or endocervical swabs 
collected from symptomatic or asymptomatic women have been 
found to have sensitivities ranging from 40% to 99% with positive 
predictive values of 31 - 96%.[10,16] Research on cost-effectiveness 
and on how best to incorporate the POC testing into current VDS 
algorithms is needed.
The very high HIV positivity among both younger and older 
women with VDS was concerning, although not unexpected. STIs 
are known to facilitate HIV acquisition, while HIV is known to 
alter the natural history of some STIs with tendencies towards 
increased severity, recurrence and poorer response to treatment.[17] 
The integration of STI and HIV prevention and treatment needs to 
be strengthened to ensure that all HIV-positive women with VDS 
and their partners are tested for HIV and those who are HIV-positive 
are linked into care, while those who are HIV-negative access risk 
reduction counselling and are provided with condoms and if eligible 
referred for pre-exposure prophylaxis for HIV. A recent national 
assessment of STI services using standardised patient actors showed 
that 61% of STI patients were offered HIV testing, 30% were provided 
with condoms and 6% of males were offered male circumcision, 
with women less likely than men to be offered relevant services. [18] 
With the development, introduction and scale-up of biomedical 
interventions such as microbicides, women with VDS should be a 
priority population for access.
Study limitations
Our analysis, which was intended to evaluate age as a criterion for 
improving the VDS algorithm, had some important limitations. This 
was a secondary analysis of sentinel surveillance data. As such, the 
variable needed to evaluate the full algorithm – such as whether or 
not the partner is symptomatic – was not available because it was not 
included in the surveillance questionnaire. Other variables such as 
knowledge of HIV status, ART use and viral suppression were not 
available, although they are important when evaluating populations 
with high HIV positivity such as ours.
Conclusions
Despite the above limitations, our study demonstrated that although 
older women with VDS were less likely to have STIs compared with 
younger women, a significant proportion of them did have STIs, and 
that age alone was not a good criterion for discriminating between 
women with and without infection with STI pathogens. Evaluation of 
the role of POC tests in improving the VDS algorithm performance 
is recommended, as is better integration of HIV and STI prevention 
and treatment.
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